Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

bribe

Trio, including former Novartis exec, accused of bribery to the tune of over HK$1.5 million

November 28, 2017
Manufacturing and Production, Sales and Marketing Novartis, bribery, illegal

A trio, including a former Senior Medical Representative at Novartis, have been charged over allegedly conspiring to offer and accept …

News
eylea-product-box-md

Regeneron forced to drop Eylea combo, advantage Novartis

November 27, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical

Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …

News

Novartis’s Tasigna scores EU approval in paediatric patients

November 20, 2017
Sales and Marketing Europe, Novartis, Tasigna, chronic myeloid leukaemia, pharma

Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …

News

NICE approves Novartis and Pfizer’s rival breast cancer drugs

November 16, 2017
Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical

NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …

News
novartis_side_building

Novartis targets specific patient population with strong Ilaris Phase 3 data

November 14, 2017
Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …

News
seqirus_08-11-17_full-42_003_web

Seqirus announces £40m UK fill-and-finish flu vaccine facility

November 9, 2017
Manufacturing and Production Liverppol, Novartis, UK, Vaccine, flu, influenza, pharma, seqirus

Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …

News
novartis_outside_1

Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time

November 8, 2017
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …

News
novartis_hq_day

Novartis aims for CAR-T double-approval in Europe

November 6, 2017
Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

News

Novartis reveals the data behind its showdown with Gilead

November 1, 2017
Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

News
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature

Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma

October 31, 2017
Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis

Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …

News
novartis_window

Novartis to bolster oncology portfolio with $3.9 billion acquisition

October 30, 2017
Sales and Marketing Advanced Acclerator Applications, Lutathera, Novartis, pharma

Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce …

News

Novartis Q3: Jimenez talks up Alcon, Gleevec takes generic hammering

October 24, 2017
Manufacturing and Production, Sales and Marketing Novartis, biotech, drugs, pharma, pharmaceutical

Novartis released its Q3 financials and, despite Gleevec dipping significantly due to generic competition, still managed to report sales of …

News

Novartis sheds generics plant and 450 jobs amid pricing pressure

October 18, 2017
Manufacturing and Production, Research and Development Novartis, US, closure, generics, manufacturing, pharma

Novartis has announced its intention to shut down its US generics manufacturing plant in Broomfield, Colorado, a move that will …

News
novartis_side_building

Novartis scores EU approval in acute myeloid leukaemia and advanced systemic mastocytosis

September 20, 2017
Research and Development, Sales and Marketing EU, Europe, Novartis, acute myeloid leukaemia, advanced systemic mastocytosis, pharma, pharmaceutical

Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications: newly …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025